Topical Issues in Diagnosis of Coagulopathies and Prevention of Thromboembolic Complications of Atrial Fibrillation in Patients with Liver Cirrhosis

Authors

  • Volodymyr Chernyavsky Bogomolets National Medical University
  • Alina Baylo Bogomolets National Medical University

DOI:

https://doi.org/10.30841/2307-5112.5-6.2020.225448

Keywords:

liver cirrhosis, atrial fibrillation, anticoagulants, coagulopathy

Abstract

Nowadays the comorbid pathology of liver cirrhosis and atrial fibrillation has been widely discussed and reported in the literature in the light of recent findings from the study of the effectiveness and safety of anticoagulants in this category of patients. The review is devoted to summarizing the existing data on the comorbid course of these diseases from the point of view of the impact of bleeding and thrombosis on the quality of life and mortality of patients and the possibility of using new methods of diagnosis and prevention of these complications.

The purpose of the review is to focus the attention of physicians and researches on the relevance and prevalence of comorbid course of liver cirrhosis and atrial fibrillation, their complications, and discuss the benefits and possibilities of applying global methods of hemostasis assessment and anticoagulants in clinical practice.

This article examines the main pathophysiological aspects of «rebalanced hemostasis» theory in liver coagulopathies, its effect on the onset of bleeding and thrombotic events, and considering the clinical benefit of the use of anticoagulants. The disadvantages of traditional coagulation assessment tests compared to the benefits of thromboelastometry (ROTEM) and thromboelastography (TEG), general fulfilling principles and evaluation of their indicators are discussed. Existing research findings on the safety and efficacy of warfarin and direct oral anticoagulants in patients with liver cirrhosis and atrial fibrillation compared with no treatment are highlighted.

Author Biographies

Volodymyr Chernyavsky, Bogomolets National Medical University

Volodymyr V. Chernyavsky,

Department of Internal Medicine No 1

Alina Baylo, Bogomolets National Medical University

Alina Ye. Baylo,

Department of Internal Medicine No 1

References

Ainscow EK et al. Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures. – Exp Opinion of Drug Safety. – 2008. – Vol.7, Issue 4. https://doi.org/10.1517/14740338.7.4.351

Alonso A, MacLehose RF, Chen LY et al. Prospective study of oral anticoagulants and risk of liver injury in atrial fibrillation patients // Heart. – 2017 Jun. – Vol.103(11). – p.834–839 doi: 10.1136/heartjnl-2016-310586

Basili S et al. Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. – Therap Adv Gastroenterol. – 2018. – Vol.11: 1756284818793561. doi: 10.1177/1756284818793561

Benjamin EJ et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. – Circulation. – 1998. – Vol.98, Issue 10. – p. 946–952 doi: 10.1161/01.cir.98.10.946.

Bhatia S et al. Atrial Fibrillation is associated with worse outcomes in patients with cirrhosis. – JACC. – March 21, 2017. – Vol.69, Issue 11. – p. 493 DOI: 10.1016/S0735-1097(17)33882-2

Bliden KP et al. Determination of nonvitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6 s system. – J Thromb Thrombolysis. – 2017. – Vol.43, Issue 4. – p. 437–445 DOI: 10.1007/s11239-017-1477-1

Caldeira D et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. – Heart. – 2014. – Vol. 100, p.550–556 DOI: 10.1136/heartjnl-2013-305288

Chokesuwattanaskul R et al. Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: A systematic review and meta-analysis. // Dig Liver Dis. – April 2019. – Vol 51, Issue 4. – p.489-495. DOI: 10.1016/j.dld.2018.12.001

Chokesuwattanaskul R et al. Epidemiology of Atrial Fibrillation in Patients with Cirrhosis and clinical significance: a metaanalysis // Eur J Gastroenterol Hepatol. – 2019. – Vol.31 Issue 4. – p. 514–519 DOI: 10.1097/MEG.0000000000001315

Chung MK et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. – Circulation. – 2020. – Vol.141, Issue 16, – p. 750-772. https://doi.org/10.1161/CIR.0000000000000748

Craig TJ et al. 2019 AHA/ACC/HRS Focused Update of the 2014 Guideline for Management of Patients with Atrial Fibrillation. // Circulation. – Vol.140 Issue 2. – p.125–151 doi.org/10.1161/CIR.0000000000000665

De Pietri L.et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology. – 2016. – Vol. 63, p. 566–573. http://dx.doi.org/10.1002/hep.28148

Dell’era et al. Review article: the relevance of portal pressure and other risk factors in acute gastro-oesophageal variceal bleeding. – Aliment Pharmacol Ther. – 2004. – Vol.3. – p. 8–15 doi: 10.1111/j.1365-2036.2004.02109.x.

Ewe K Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci. – 1981. – Vol. 26, p. 388–393.

Gallagher C et al. Anticoagulation for Atrial Fibrillation in Cirrhosis of the Liver: Are Low-Dose Non-Vitamin K Oral Anticoagulants a Reasonable Alternative to Warfarin? // J Am Heart Assoc. – 2019. –Vol.8, Issue 5. DOI: 10.1161/JAHA.119.012102

George G at all. Reproducibility of TEG Parameters in Stable Cirrhotics. // Lab Med. – August 2018. – Vol. 49, Issue 3. – p. 226–230. DOI: 10.1093/labmed/lmx041

Gonzalez E et al. Trauma Induced Coagulopathy. Rotational Thromboelastometry (ROTEM). Switzerland: Springer International Publishing, 2016: 611

Han H et al. Atrial fibrillation in hospitalized patients with end‐stage liver disease: temporal trends in prevalence and outcomes. – Liver Int. –2020. – Vol. 40, Issue 3. – p. 674–684. https://doi.org/10.1111/liv.14291

Harrison MM. The Misunderstood Coagulopathy of Liver Disease: A Review for the Acute Setting. // Western Journal of Emergency Medicine. – September 2018. – Vol. 19. – p. 863–871. doi: 10.5811/westjem.2018.7.37893

Hickman IJ et al. Altered clot kinetics in patients with non-alcoholic fatty liver disease. – Ann Hepatol. – 2009. – Vol.8, Issue 4. – p. 331–338. DOI: 10.1016/S1665-2681(19)31746-6

Hsin-Fu Lee et al. Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients with Nonvalvular Atrial Fibrillation. //J Am Heart Assoc. – 2019. – Vol. 8, Issue 5. DOI: 10.1161/JAHA.118.011112

Hum J et. all. Thromboelastography Better Reflects Hemostatic Abnormalities in Cirrhotics Compared with the International Normalized Ratio // Journal of Clin. Gastroenterology. – Nov 19, 2019. DOI: 10.1097/MCG.0000000000001285

Kirchhov P, Benussi S, Ahlsson A et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. – 2016, – Eur Heart J. – Vol.37, p. 2893–2962

Kleinegris M.C et al..Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J Thromb Haemost. – 2014. – Vol.12, Issue 10, p. 1647–1657. http://dx.doi.org/10.1111/jth.12706

Lee SJ et all. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis // Int J Cardiol. – 2015. – Vol.180. – p.185–191 DOI: 10.1016/j.ijcard.2014.11.183

Lentschener C. et al. Assessment of haemostasis in patients with cirrhosis: Relevance of the ROTEM tests?: A prospective, cross-sectional study // Eur J Anaesthesiol. – 2016. – Vol. 33, p. 126–133. DOI: 10.1097/EJA.0000000000000322

Leonardi F et al. Anticoagulation in cirrhosis: a new paradigm? // Clinical and Molecular Hepatology. – 2017. – Vol. 23, Issue 1. – p. 13–21. doi: 10.3350/cmh.2016.0110

Ling Kuo et all. Liver Cirrhosis in Patients with Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention? // J Am Heart Assoc. 2017. – Vol. 6, Issue 6. DOI: 10.1161/JAHA.116.005307

Lip GY Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score // J Am Coll Cardiol. – Jan 2011. – Vol. 57 Issue 2. – p. 173–180. doi: 10.1016/j.jacc.2010.09.024

Maan R et al. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies // Drugs. – 2015. – Vol.75, Issue 17. – p. 1981–1992. doi: 10.1007/s40265-015-0480-0

Mannucci PM, Tripodi A. Liver disease, coagulopathies and transfusion therapy // Blood Transfusion. – 2013 Jan. – Vol.11(1). – p. 32–36. DOI 10.2450/2012.0151-12

Mwalitsa et al. Atrial Fibrillation in Patients with Cirrhosis // Liver Int. – 2016 Mar. – Vol. 36, Issue 3. – p. 395–400. DOI: 10.1111/liv.12928

Nguyen B et al. A case-report of successful use of thromboelastography to manage anticoagulation therapy in a patient with concomitant catastrophic antiphospholipid syndrome and heparininduced thrombocytopenia. // Blood Coagul Fibrinolysis. – 2019. – Vol. 30, Issue 4. – p. 171–175. DOI: 10.1097/MBC.0000000000000810

O’Leary JG et al. AGA Clinical Practice Update: Coagulation in Cirrhosis // Gastroenterology. – 2019. – Vol. 157. – p. 34–43. DOI: 10.1053/j.gastro.2019.03.070

Peterson TJ et al. Use of thromboelastography in the management of liver cirrhosis and accelerated intravascular coagulation and fibrinolysis (AICF) // BMJ Case Rep. – 2016. DOI: 10.1136/bcr-2016-218294

Qamar A et al. Oral Anticoagulation in Patients With Liver Disease // J Am Coll Cardiol. – 2018. – Vol. 71(19), p. 2162–2175. doi: 10.1016/j.jacc.2018.03.023

Renda G et al. Net Clinical Benefit of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials // The American Journal of Medicine. – 2015. – Vol.128. – p. 1007–1014. DOI: 10.1016/j.amjmed.2015.03.034

Rossetto V. et al. Whole blood rotation thromboelastometry (ROTEM(R)) profiles in subjects with non-neoplastic portal vein thrombosis // Thromb Res. – 2013. – Vol.132, p. 131–134. http://dx.doi.org/10.1016/j.thromres.2013.06.009

Saner FH, et al. Monitoring and Treatment of Coagulation Disorders in End-Stage Liver Disease // Visc Med. – 2016. – Vol. 32. – p. 241–248. DOI: 10.1159/000446304

Segal JB, Dzik WH Transfusion Medicine/Hemostasis Clinical Trials Network: Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review // Transfusion, 2005. – Vol. 45, p. 1415–1425.

Seyve L et al. Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM) // Int J Lab Hematol. – 2018. – Vol. 40, Issue 1. – p. 84–93. doi: 10.1111/ijlh.12744

Shin KH, et al. Thromboelastographic Evaluation of Coagulation in Patients with Liver Disease // Ann Lab Med. – 2017.– Vol.37(3). – p. 204–212. DOI: 10.3343/alm.2017.37.3.204

Solbeck S et al. The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thromboelastography (TEGR), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT) // Scand J Clin Lab Invest. – 2018. – Vol.78. – p. 25–30. DOI: 10.1080/00365513.2017.1408138

Solbeck S et al. Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests // Int J Cardiol. – 2016. – Vol. 208. – p. 14–18. DOI: 10.1016/j.ijcard.2016.01.148

Spronk H et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation // Eur Heart J – Jan 2017. – Vol. 38, Issue 1. – p. 38–50. https://doi.org/10.1093/eurheartj/ehw119

Staerk L. et al. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes // Circ Res. – 2017. – Vol. 120, Issue 9. – p. 1507–1517. doi:10.1161/CIRCRESAHA.117.309732

Steffel J et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation // Eur Heart J. – 2018. – Vol.39. – p. 1330–1393. doi:10.1093/eurheartj/ehy136

Steinberg BA et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) // Am Heart J. – 2014. – Vol. 167, Issue 5. – p. 735–742. doi: 10.1016/j.ahj.2014.02.003

Stravitz RT et al. Bleeding complications in acute liver failure // Hepatology. – 2018. – Vol. 67, Issue 5. – p. 1931–1942. doi: 10.1002/hep.29694

Tripodi A, Mannucci PM. The Coagulopathy of Chronic Liver Disease // N Engl J Med. – 2011. – Vol 365. – p. 147–156. DOI: 10.1056/NEJMra1011170

Tripodi A. Et al.The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters // Thromb Res. – 2009. – Vol 124, p. 132–136. http://dx.doi.org/10.1016/j.thromres.2008.11.008

Weinberg EM et al. Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis // Semin Liver Dis. – 2019. – Vol. 39. – p. 195–208. DOI: 10.1055/s-0039-1679934

Published

2021-03-15

Issue

Section

For practicing physicians